Teva Pharmaceutical Industries and Eagle Pharmaceuticals announced that the FDA has approved Bendeka (bendamustine hydrochloride) injection, formerly EP 3102, a...
Pfizer Inc. has announced that the FDA has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral...
Pfizer Inc. announced that the FDA Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory...
The FDA has approved supplemental New Drug Applications for three type 2 diabetes medicines within the empagliflozin family to include...
Cardiome Pharma Corp. announced that it has received a response from the FDA regarding the regulatory path for Brinavess (vernakalant...
Janssen Research & Development has submitted to the FDA a New Drug Application (NDA) for Invokamet XR, a once-daily therapy...
Harrow Health , an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, jointly announced the FDA approval of IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia
This article was created from a comprehensive literature search with information taken from meta-analyses, systematic reviews, and clinical trials of children and adults.
Shire announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant Intuniv (guanfacine hydrochloride prolonged release tablets) for the...
Alcon, a division of Novartis, has received approval from the FDA of Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7%, for the...
